Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

KaloBios Announces Martin Shkreli’s Sale of His Stake in the Company

By Globe Newswire | August 30, 2016

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the sale by Martin Shkreli of his remaining shares of KaloBios common stock, fully eliminating his association with the company. KaloBios also outlined its priority goals as it continues to transform the company.

In private transactions, Shkreli sold his entire stake in KaloBios directly to other investors. Shkreli has zero ownership of the capital stock of, or ongoing financial interest in, the company. In addition, under the terms of the governance agreement announced July 7, Shkreli continues to be restricted from certain further actions concerning the company for a period of time.

“This transaction enhances our flexibility to execute the company’s strategy by removing an impediment to progress,” said Cameron Durrant, MD, KaloBios chairman and CEO. “The new KaloBios strategy is to leverage available U.S. regulatory incentives as a framework to swiftly and cost-effectively advance and strengthen our portfolio for neglected and rare diseases, with an interest in pediatric conditions.”

KaloBios has set out key near-term goals in executing this strategy:  

  • Benznidazole – expect to have U.S. Food and Drug Administration (FDA) Pre-Investigational New Drug (IND) application meeting within the next six months to confirm the regulatory pathway for benznidazole in the treatment of Chagas disease, a neglected tropical disease.
  • Lenzilumab – continue enrolling patients in the company’s ongoing Phase 1 study of lenzilumab for Chronic Myelomonocytic Leukemia (CMML), with the expectation to use the data to help inform a possible study in Juvenile Myelomonocytic Leukemia (JMML), a rare pediatric condition.
  • Corporate – regain compliance with periodic reporting requirements of the Securities and Exchange Commission, and seek relisting on a national stock exchange.

Durrant stated, “We have come a long way quickly—overcoming obstacles, establishing the framework for success and leveraging a hard-driving mindset to advance our pipeline. Our differentiated strategy is gaining traction and we will continue to execute our plan through transformational models, such as responsible pricing and innovative internal and external approaches.”

KaloBios emerged from Chapter 11 bankruptcy June 30 with $14 million in equity financing. The company acquired the rights from Savant Neglected Diseases LLC to develop benznidazole for the treatment of Chagas disease and has initiated a Phase 1 study of its monoclonal antibody candidate lenzilumab for the treatment of CMML.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!  

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE